PTJ
MRSN

Paul Tudor Jones’s Mersana Therapeutics MRSN Stock Holding History

Paul Tudor Jones’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,720
Closed -$271K – 2368
2022
Q1 		$271K Buy
+2,720
New +$318K 0.01% 1607
2021
Q3 		– Sell
-418
Closed -$142K – 2676
2021
Q2 		$142K Buy
+418
New +$158K ﹤0.01% 1515
2017
Q4 		– Sell
-800
Closed -$346K – 1197
2017
Q3 		$346K Sell
800
-2,031
-72% -$800K 0.01% 773
2017
Q2 		$989K Buy
+2,831
New +$979K 0.03% 341

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Paul Tudor Jones's MRSN Position: Q2 2022 in Review

Paul Tudor Jones sold out of Mersana Therapeutics (MRSN) in Q2 2022, closing a stake of 2,720 shares — an estimated $271K sold.

Paul Tudor Jones first reported a position in MRSN in Q2 2017 and held it in 4 quarters. The position peaked at $989K in Q2 2017. 126 funds tracked by Wall St. Rank hold MRSN as of Q2 2022.

  • Paul Tudor Jones reported no remaining Mersana Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Paul Tudor Jones sold 2,720 Mersana Therapeutics shares in Q2 2022, an estimated $271K.
  • Paul Tudor Jones first reported a position in Mersana Therapeutics in Q2 2017 and held it in 4 quarters.
  • Paul Tudor Jones's Mersana Therapeutics position peaked at $989K in Q2 2017.
  • 126 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2022.

Based on Tudor Investment Corp's 13F filing for Q2 2022, filed 15 Aug 2022.